rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2008-5rsp-289Research ArticleСтатьиArticlesРИТУКСИМАБ новые перспективы лечения больных СКВRITUKSIMAB novye perspektivy lecheniya bol'nykh SKVSolov'evS KSolov'evS K-200815022008461s№1s (2008)2933Copyright © Solov'ev S.K., 20082008Solov'ev S.K.Solov'ev S.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/289References<div><p>Lipsky РЕ. Systemic lupus erythematosus: an autoimmune disease of В cell hyperactivity. Nat Immunol. 2001;2:764-766.</p><p>Silverman GJ. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum. 2005;52:371- 377</p><p>Vasoo S, Hughes GRV Perspectives on the changing face of lupus mortality. Autoimmun Rev. 2004;3:415-417.</p><p>Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 1996;39:1475-1482.</p><p>Chambers SA, Isenberg DA Anti - В cell therapy (Rituximab) in the treatment of autoimmune disease. Lupus. 2005; 14:210214.</p><p>John Looney, Jennifer H. Anolik, Debbie Campbell, Raymond E. Felgar et al. В Cell Depletion as a Novel Treatment for Systemic Lupus Erythematosus A Phase I/ll Dose-Escalation Trial of Rituximab Arthritis Rheum. 2004;Aug;8:2580-2589.</p><p>Sfikakis PP, Boletis JN, Lionaki S., Vigklis V., Fragiadaki KG, Iniotaki A., and Moutsopoulos HM Remission of Proliferative Lupus Nephritis Following В Cell Depletion Therapy Is Preceded by Down-Regulation of the T Cell Costimulatory Molecule CD40 Ligand An Open-Label Trial. Arthritis Rheum. 2005;52(2):501-513.</p><p>Mikiko Tokunaga et al. Efficacy of rituximab (Anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. 15 Nov 2006; Ann Rheum Dis</p><p>C.K. Соловьев, Е.Л. Насонов, М.А.Котовская. Ритуксимаб в лечении системной красной волчанки. Русский Медицинский журнал, 2005, 26, 1731-1736.</p><p>Е.Л. Насонов, С.К. Соловьев. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при воспалительных ревматических заболеваниях. Научно-практическая ревматология 1, 2007,4-8.</p></div><br /><div><p>Lipsky РЕ. Systemic lupus erythematosus: an autoimmune disease of В cell hyperactivity. Nat Immunol. 2001;2:764-766.</p><p>Silverman GJ. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum. 2005;52:371- 377</p><p>Vasoo S, Hughes GRV Perspectives on the changing face of lupus mortality. Autoimmun Rev. 2004;3:415-417.</p><p>Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 1996;39:1475-1482.</p><p>Chambers SA, Isenberg DA Anti - В cell therapy (Rituximab) in the treatment of autoimmune disease. Lupus. 2005; 14:210214.</p><p>John Looney, Jennifer H. Anolik, Debbie Campbell, Raymond E. Felgar et al. В Cell Depletion as a Novel Treatment for Systemic Lupus Erythematosus A Phase I/ll Dose-Escalation Trial of Rituximab Arthritis Rheum. 2004;Aug;8:2580-2589.</p><p>Sfikakis PP, Boletis JN, Lionaki S., Vigklis V., Fragiadaki KG, Iniotaki A., and Moutsopoulos HM Remission of Proliferative Lupus Nephritis Following В Cell Depletion Therapy Is Preceded by Down-Regulation of the T Cell Costimulatory Molecule CD40 Ligand An Open-Label Trial. Arthritis Rheum. 2005;52(2):501-513.</p><p>Mikiko Tokunaga et al. Efficacy of rituximab (Anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. 15 Nov 2006; Ann Rheum Dis</p><p>C.K. Соловьев, Е.Л. Насонов, М.А.Котовская. Ритуксимаб в лечении системной красной волчанки. Русский Медицинский журнал, 2005, 26, 1731-1736.</p><p>Е.Л. Насонов, С.К. Соловьев. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при воспалительных ревматических заболеваниях. Научно-практическая ревматология 1, 2007,4-8.</p></div><br />
The authors declare that there are no conflicts of interest present.